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ABSTRACT
Lsm1 is a component of the Lsm1-7 complex
involved in cytoplasmic mRNA degradation. Lsm1
is over-expressed in multiple tumor types, including
over 80% of pancreatic tumors, and increased levels
of Lsm1 protein have been shown to induce carcin-
ogenic effects. Therefore, understanding the per-
turbations in cell process due to increased Lsm1
protein may help to identify possible therapeutics
targeting tumors over-expressing Lsm1. Herein, we
show that LSM1 over-expression in the yeast
Saccharomyces cerevisiae inhibits growth primarily
due to U6 snRNA depletion, thereby altering pre-
mRNA splicing. The decrease in U6 snRNA levels
causes yeast strains over-expressing Lsm1 to be
hypersensitive to loss of other proteins required
for production or function of the U6 snRNA, support-
ing a model wherein excess Lsm1 reduces the avail-
ability of the Lsm2-7 proteins, which also assemble
with Lsm8 to form a complex that binds and stabi-
lizes the U6 snRNA. Yeast strains over-expressing
Lsm1 also display minor alterations in mRNA decay
and demonstrate increased susceptibility to muta-
tions inhibiting cytoplasmic deadenylation, a pro-
cess required for both 5’-to-3’ and 3’-to-5’
pathways of exonucleolytic decay. These results
suggest that inhibition of splicing and/or deadenyla-
tion may be effective therapies for Lsm1-over-
expressing tumors.
INTRODUCTION
Tumors of the pancreas pose a critical problem in elim-
inating mortality due to cancer in that incidence and mor-
bidity rates for this disease are nearly equal (NCI SEER
database, http://seer.cancer.gov/statfacts/html/pancreas
.html). Even with recent technological advances in geno-
mic analysis, the overall relative 5-year survival rate of
pancreatic tumors from 1996 to 2004 was 5.1%, and
trend analysis of the period from 2003 to 2005 revealed
no signiﬁcant changes in mortality rate (NCI SEER data-
base, http://seer.cancer.gov/statfacts/html/pancreas.html).
Given that the current prognosis for patients with these
tumors is dismal, it is vital that we search for novel ther-
apeutics targeting this disease.
In 1997, Lsm1 was identiﬁed through subtractive
hybridization cloning in pancreatic cancer cells (1) and
was shown to be over-expressed in 87% of pancreatic
cancers. Subsequently, its over-expression has been
described in 40% of prostate cancers (2), a subset
(15–20%) of breast cancers that are ampliﬁed at the
8p11-12 region (3,4) and most recently in lung cancers
and mesotheliomas (5). The direct involvement of Lsm1
in carcinogenesis in these tissues has been demonstrated
through analyses of Lsm1’s eﬀects on growth and anchor-
age dependence (2,6,7), contact inhibition (2), autocrine
activity (7) and tumor establishment and metastases
(2,6,8,9). The increase in Lsm1 levels in these tumors is
moderate (about 2- to 5-fold) (7), suggesting that subtle
changes in the levels of Lsm1 can aﬀect the growth proper-
ties of mammalian cells. Thus, it is important to elucidate
the processes aﬀected by LSM1 over-expression in order
to provide new targets for therapeutic development
against pancreatic and other Lsm1-over-expressing
cancers.
Lsm1 over-expression could aﬀect cellular metabolism
in several manners. For example, Lsm1 over-expression
has been suggested to destabilize certain tumor suppressor
transcripts, allowing for carcinogenesis (2). This model is
based on the fact that Lsm1 in yeast and humans assem-
bles with the Lsm2-Lsm7 proteins to form a heterohepta-
meric Lsm1-7 complex that binds mRNAs, components of
the decapping machinery, and promotes mRNA decap-
ping and degradation (10–14). Alternatively, Lsm1 over-
expression might inhibit the function of the related
Lsm2-8 complex, wherein the Lsm1 protein is replaced
by the Lsm8 protein. The Lsm2-8 complex binds the
30-end of the U6 snRNA protecting it from degradation
and thereby allowing normal rates of pre-mRNA splicing
(15–17). Consistent with Lsm1 over-expression aﬀecting
the nuclear Lsm2-8 complex, over-expression of LSM1
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Lsm7p (18). Hence, over-expression of LSM1 may actu-
ally reduce U6 levels and selectively inﬂuence splicing,
allowing for carcinogenesis.
To understand how Lsm1 over-expression inﬂuences
cell processes, we took advantage of the conservation of
Lsm1 function in both budding yeast and humans to
determine how Lsm1 over-expression aﬀects RNA metab-
olism in yeast. We found that over-expression of LSM1
in the yeast Saccharomyces cerevisiae leads to defects in
pre-mRNA splicing, which is caused by decreased levels
of the U6 snRNA. The splicing defect causes yeast strains
over-expressing Lsm1 to be hypersensitive to loss of other
components required for maintaining levels of U6
snRNA. Moreover, yeast strains over-expressing Lsm1
are more susceptible to mutations inhibiting cytoplasmic
deadenylation, which is normally a prerequisite for
mRNA decay. These results suggest that inhibition of
splicing and/or deadenylation may be eﬀective therapies
for LSM1-over-expressing tumors.
MATERIALS AND METHODS
Yeast strains, growth conditions and plasmids
The genotypes of the strains used are listed in
Supplementary Table S3. Cells were cultured in either
yeast extract/peptone medium or synthetic medium sup-
plemented with appropriate amino acids and 2% sugar
(sucrose or galactose) and were grown at 308C. Yeast
strains were transformed as previously described (19)
and maintained in the appropriate selective media. Over-
expression studies were performed by culturing strains
continuously in galactose. Plasmids utilized in this study
are found in Supplementary Table S4.
Plasmid construction
The GAL LSM1 2m plasmid was constructed by amplify-
ing the LSM1 coding region 64nt prior to its start through
240nt following the stop. A BamHI restriction site
immediately upstream of the 50-end and a SalI restriction
site at the 30-end of this product facilitated its ligation to a
GAL 2m vector (pRP861) and placed the LSM1 gene
under transcriptional control of a GAL promoter. The
GAL LSM1 CEN plasmid was constructed by amplifying
the LSM1 coding region 59nt prior to its start through
240nt following the stop. A SacI restriction site immedi-
ately upstream of the 50-end and a SalI restriction site
at the 30-end of this product facilitated its ligation to a
GAL CEN vector (pRP23) and placed the LSM1 gene
under transcriptional control of a GAL promoter.
RNA analysis
RNA analyses were performed as previously described
(20). Total RNA was isolated (21) from midlog cultures
grown in appropriate media, and 20mg of each sam-
ple were electrophoresed on 6% acrylamide, 8M Urea
gels. Northern blots were performed using the indicated
oligonucleotides radiolabelled with
32P at the 50-end.
Oligonucleotides used in this study are detailed in
Supplementary Table S5.
For decay time course experiments, transcriptional
shutoﬀ was achieved by resuspending galactose-induced
cultures in media containing 4% dextrose (22) and then
collecting samples over a brief time course.
Protein analysis
Midlog cultures were collected and harvested for protein
analysis. Samples were lysed using 5M urea, boiled, then
vortexed in glass beads for 5min. A solution of 125mM
Tris–Cl pH 6.8, 2% SDS was added at 2.5  the volume of
5M urea used, and this was vortexed into the mixture,
then samples were boiled a second time. Collected lysate
was clariﬁed by spinning at 16000 RCF, and the super-
natant was resuspended in protein loading buﬀer (0.05M
Tris pH 6.5, 1% SDS, 0.01% bromophenol blue, 10%
glycerol), boiled, and run on a 12% Tris–SDS acrylamide
gel. Gels were transferred to nitrocellulose and probed
using standard Western blotting protocols using an
antibody to Lsm1 (a generous gift of Allen Sachs and
Karsten Weis) and an anti-rabbit secondary coupled to
HRP (Pierce). Lsm1 signal was revealed using Pierce
SuperSignal West Dura and exposing the blots to ﬁlm
and developing in a ﬁlm processor (Konica).
Films were scanned into .tif format using an HP Scanjet
Pro ﬂatbed scanner, and images were analyzed and
quantitated in Adobe Photoshop following the method
outlined at http://www.lukemiller.org/journal/2007/08/
quantifying-western-blots-without.html. References from
Supplementary Tables are Table S3 (23–25) and
Table S4 (26–28).
RESULTS
LSM1 over-expression in yeast can affect cell growth
In order to understand the eﬀects of LSM1 over-
expression in budding yeast, we ﬁrst expressed LSM1
from the GAL promoter on a CEN plasmid in a wild-
type yeast strain. To determine the degree of over-
expression, we utilized antisera against Lsm1 to determine
the increase in the Lsm1 protein levels as compared to a
vector only control strain. We observed that strains trans-
formed with a GAL-LSM1 centromere plasmid showed
 3  the levels of wild-type yeast strains (Figure 1A and
B), an increase in levels similar to what is seen in various
human tumor cell lines. We observed that cells carrying
this plasmid exhibited a slight decrease in growth as com-
pared to the same strain carrying the vector backbone,
although the strains were still able to grow at some rate
(Figure 1C, uppermost panel). Thus, over-expression of
LSM1 inhibits, but does not completely prevent, the
growth of wild-type yeast strains.
LSM1 over-expression shows genetic interactions with
proteins affecting the U6 snRNP and mRNA deadenylases
There are two likely possibilities for how LSM1 over-
expression might aﬀect cell function. First, since the
Lsm1-7 complex functions in the control of mRNA
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chiometry of components of the decapping complex,
enhancing or inhibiting mRNA decapping and thereby
aﬀecting growth. Alternatively, increased levels of
Lsm1p could deplete the nuclear Lsm2-8 complex, thus
aﬀecting cell growth through inhibition of splicing. To
consider these possibilities, we ﬁrst examined the eﬀects
of Lsm1 over-expression from the GAL CEN plasmid in
lsm7D and lhp1D strains, which are both compromised for
U6 levels (15, 29–32). We observed that over-expression of
Lsm1 strongly limited the growth of both lsm7D and lhp1D
strains, with the strongest eﬀect seen with lsm7D
(Figure 1C, lower panels).
In order to extend this genetic analysis, we decided to
over-express Lsm1 from the GAL promoter on a multi-
copy 2m plasmid, thereby increasing the probability of us
detecting additional genetic interactions. We observed
that over-expression from the GAL 2m plasmid gave a
stronger inhibition of growth than the GAL centromere
plasmid (compare Figure 1C uppermost panel and
Figure 2A), although the cells do still grow at a reduced
rate (Figure 2A). Using this system of expressing LSM1
from the GAL 2m plasmid, we then examined Lsm1 over-
expression in a variety of yeast strains lacking non-
essential proteins that function in pre-mRNA splicing
or mRNA degradation. A complete list of these mutants
and their phenotypic eﬀects observed with LSM1
over-expression is provided in Supplementary Tables S1
and S2.
Our broader genetic analysis revealed that factors inter-
acting with U6 snRNA were indeed important for growth
when Lsm1 was over-expressed. Expressing LSM1 from
the GAL 2m plasmid still demonstrated strong synthetic
growth defects with strains deleted for LSM7 or LHP1
(Figure 2B). Furthermore, snu66D, which removes a
Figure 1. Moderate levels of Lsm1 aﬀect cell growth. (A) LSM1 over-
expression on a GAL CEN plasmid yields 2- to 4-fold protein expres-
sion. (B) Quantitative analysis of Lsm1 over-expression. (C) LSM1
over-expression on a GAL CEN plasmid aﬀects growth and yields syn-
thetic growth defects with strains mutant for U6 snRNP function. (A,
B, C) OE CEN=Lsm1 expressed on GAL CEN plasmid (pRP1851).
V=CEN vector (pRP23). (A) Western blot. Strains were transformed
as indicated. ‘Lsm1 protein’ labels the position of Lsm1 band that was
quantitated. Asterisk marks a cross-reacting band used for normali-
zation. WT=yRP841, lsm1D=yRP1365. (B) Quantitation of pro-
tein levels. Relative intensities were compared to yield fold increase
in Lsm1 protein levels over wild-type control. Four comparisons
were made of OE CEN to v. Error bars represent standard deviation
(see ‘Materials and Methods’ section, protein analysis for details
on protocols used in A and B). (C) BY4741(WT) and isogenic dele-
tion strains transformed as indicated and were frog ponded by
10-fold dilutions and plated on plates containing galactose and grown
at 308C.
Figure 2. LSM1 2m over-expression aﬀects cell growth. (A) LSM1
over-expression on a GAL 2m plasmid aﬀects growth of wild-type
yeast. (B) LSM1 over-expression on a GAL 2m plasmid yields synthetic
growth defects with strains mutant for U6 snRNP or (C) deadenylase
functions. BY4741(WT) (A) and isogenic deletion strains (B,C) trans-
formed with either the GAL-LSM1 2m plasmid construct (pRP1840,
OE) or GAL 2m plasmid control (pRP861, V) were frog ponded by
10-fold dilutions and plated on plates containing the indicated sugar
and grown at 308C.
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showed a strong exacerbation of the growth defect
observed when LSM1 was over-expressed from the GAL
2m plasmid (Figure 2B). Taken together, these results sug-
gest that LSM1 over-expression may interfere with growth
by inhibiting U6 snRNA biogenesis or function.
We also observed that over-expressing LSM1 displayed
strong synthetic growth defects with deletions of the
CCR4 and POP2 genes, which are key components of
the predominant mRNA deadenylase (35). As seen in
Figure 2C, expression of GAL-LSM1 on a 2m plasmid
in strains deleted for CCR4 or POP2 inhibited growth
more strongly than over-expression in a wild-type strain
(Figure 2A). Signiﬁcant synthetic growth defects were
not demonstrated with deletions in many other decay fac-
tors (Supplementary Table S1), including strains deleted
for PAT1, DHH1, and EDC3 (Figure 2C), which encode
factors that enhance decapping and/or translational
repression (13,22,36,37). The enhanced toxicity of Lsm1
over-expression in the ccr4D and pop2D strains suggests
that mRNA decay might be altered when Lsm1 is over-
expressed, increasing the relative requirement for
deadenylation.
LSM1 over-expression induces defects in splicing
Since strains lacking LSM7, LHP1, and SNU66 are defec-
tive for U6 or U4/U6/U5 snRNP function (29,32,34), we
hypothesized that LSM1 over-expression might further
interfere with splicing in these deletion strains. To assess
the eﬀects of Lsm1 over-expression on splicing we exam-
ined the accumulation of the intron-containing precursor
to the U3 snoRNA, which is a sensitive measure of splic-
ing in budding yeast (29). In this analysis, we also included
the ccr4D and pop2D strains, in case these mutations had
some previously unobserved eﬀect on splicing. For this
experiment, cells containing the GAL-LSM1 2m plasmid,
or a vector control, were continuously grown in galactose,
cells were harvested at mid-log, and the RNA was ana-
lyzed on northern blots for the U3 snoRNA.
We observed that over-expression of Lsm1 in a wild-
type strain did not lead to accumulation of the intron-
containing precursor to the U3 snoRNA (pre-U3
snoRNA). However, over-expression of Lsm1 in an
lsm7D strain, increased the accumulation of the pre-U3
snoRNA seen in this strain (Figure 3A, compare lanes 3
and 4). Similarly, a snu66D strain accumulated small
amounts of the pre-U3 snoRNA, and these levels
increased with LSM1 over-expression (Figure 3A, com-
pare lanes 7 and 8). In an lhp1D strain, no pre-U3
snoRNA was evident, and small amounts accumulated
with Lsm1 over-expression, which were visible on longer
exposures (Figure 3A, compare lanes 5 and 6). Finally,
ccr4D and pop2D strains failed to accumulate pre-U3
snoRNA with or without LSM1 over-expression
(Figure 3A, examine lanes 9 through 12). Moreover, in a
similar analysis, over-expressing LSM1 on the GAL CEN
plasmid demonstrated similar synthetic splicing defects in
strains deleted for LSM7 or LHP1 as compared to vector
only controls (Figure 3B, compare lane 3–4 and lane 5–6).
These results indicate that Lsm1 over-expression can lead
to defects in splicing, even at moderate levels of over-
expression as observed in tumors (7), which are most
easily revealed in strains lacking proteins aﬀecting U6
snRNA biogenesis or function.
Figure 3. LSM1 over-expression inhibits splicing by aﬀecting U6
snRNA. (A) LSM1 over-expression (GAL 2m) inhibits splicing of
U3 snoRNA in some U6 snRNP defective strains. (B) LSM1 over-
expression (GAL CEN) inhibits splicing of U3 snoRNA in some U6
snRNP defective strains. OE 2m=GAL-LSM1 2m plasmid construct
(pRP1840). OE CEN=GAL-LSM1 CEN plasmid (pRP1851).
V=appropriate vector control (pRP861 or pRP23). (A, B, C) Total
RNA (20mg) from BY4741(WT) and isogenic deletion strains trans-
formed as indicated were electrophoresed on 8M Urea, 6% acrylamide
gels and blotted by northern using a probe for U3 snoRNA. U14
snoRNA or SCR1 RNA is included as a normalization control.
Marker sizes are indicated. (C) Upper panel. LSM1 over-expression
depletes levels of U6 snRNA. Separate blot, processed as in (A), but
probed for U6 snRNA. Lower panel. Histogram of U6 levels (normal-
ized to U14 levels) expressed as a fraction of levels for wild-type expres-
sing the control plasmid. Results are an average of three experiments
with error bars representing the standard deviation.
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U6 snRNA levels
A simple hypothesis for how Lsm1 over-expression leads
to defects in splicing is that Lsm1 over-expression reduces
the levels of the Lsm2-8 complex, which binds to and
stabilizes the U6 snRNA (17,29). This hypothesis predicts
that the levels of U6 snRNA should be reduced by Lsm1
over-expression. To test this prediction, we examined the
levels of U1, U2, U4, U5 and U6 snRNAs in both wild-
type and various mutant strains over-expressing Lsm1.
We observed that over-expressing LSM1 on a GAL 2m
plasmid had little eﬀect on U1, U2, U4 and U5 snRNA
levels (Figure 3C and data not shown), but U6 levels were
decreased in all cells over-expressing LSM1. Speciﬁcally,
in wild-type cells over-expressing LSM1 on a GAL 2m
plasmid, U6 snRNA levels decreased by an average of
2-fold (Figure 3C, compare lane 2 to 1 and histogram),
and this level of U6 depletion was also observed when
moderately over-expressing LSM1 on a GAL CEN plas-
mid (data not shown). Moreover, and consistent with the
genetic interactions, U6 levels were most depleted (4.5-fold
less on average, Figure 3C histogram) in an LSM7 dele-
tion background over-expressing LSM1 on a GAL 2m
plasmid when compared to wild-type expressing a vector
control (Figure 3C, examine lanes 3 and 2 and histogram).
In these two instances, the results imply that LSM1 over-
expression exerts its inhibition of growth through a reduc-
tion of U6 levels, yielding an inhibition of splicing.
However, the levels of U6 snRNA in lhp1D, snu66D,
ccr4D, and pop2D strains over-expressing LSM1 on a
GAL 2m plasmid were not consistently lower than that
of a wild-type strain over-expressing LSM1. These results
suggest that the consequences of Lsm1 over-expression on
growth can be made more signiﬁcant without further
reductions in the U6 level. In the case of the snu66D,
this eﬀect may be due to the assembly of a defective
U4/U6/U5 tri- snRNP, whereas the growth inhibition in
the ccr4D and pop2D strains may be due to defects in
mRNA decay (see ‘Discussion’ section).
Depletion of U6 is responsible for synthetic growth and
splicing defects in wild-type, lsm7D and lhp1D
strains over-expressing LSM1
The decrease in U6 snRNA levels with Lsm1 over-
expression suggests that the inhibition of growth in wild-
type and possibly various mutant strains could be due
to the decreased U6 snRNA levels. This hypothesis pre-
dicts that the growth and splicing defects due to Lsm1
over-expression should be reversed by increasing levels
of U6. To test this possibility, we introduced a high-
copy plasmid expressing U6 snRNA into each strain and
examined its eﬀects on growth and splicing in the presence
and absence of Lsm1 over-expression from a GAL 2m
plasmid.
Our results revealed that at least some of the growth
defects due to LSM1 over-expression are attributable
to low levels of U6 snRNA. First, over-expression of U6
snRNA suppressed the growth defect seen in wild-type
cells due to Lsm1 over-expression (Figure 4, uppermost
panel). Second, consistent with its severe growth defects
and U6 snRNA reduction, lsm7D over-expressing LSM1
was nearly completely rescued by the increased U6
expression (Figure 4) and U6 snRNA over-expression sup-
pressed the splicing defect seen with Lsm1 over-expression
in this strain (Figure 5, compare lanes 5, 6 and 7). Third, a
similar complementation of synthetic growth defects was
observed in lhp1D over-expressing LSM1 when U6 was
over-expressed (Figure 4). These observations indicate
that at least some of the growth and splicing defects
in LSM1-over-expressing strains arise from depletion in
the levels of U6.
However, the growth defects in the snu66D strain were
not rescued by over-expression of U6 snRNA (Figure 4).
We speculate that the synthetic growth defects in the
snu66D strain may be due to the assembly of a U6
snRNA that is compromised in function due to loss of
both the Snu66p and the Lsm2-8 complex. Consistent
with that possibility, over-expression of U6 snRNA did
not suppress the splicing defect seen in the snu66D strain
(Figure 5, compare lanes 9, 10 and 11). This suggests that
Figure 4. Growth defects due to LSM1 over-expression can be rescued
by increasing levels of U6. Increasing U6 levels rescues synthetic
growth defects in wild-type, lsm7D and lhp1D strains. BY4741(WT)
and isogenic deletion strains. Transformation of strains as indicated:
‘+’ in a column indicates expression of either GAL-LSM1 2m
(pRP1840, OE 2m LSM1) and/or pSNR6 (OE U6), ‘–’ indicates that
the control vector was used. Frog ponds are by 10-fold dilutions onto
plates containing the indicated sugar, grown at 308C.
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may contribute directly to U6 snRNP function (see
‘Discussion’ section).
We observed that the ccr4D and pop2D strains were
partially rescued by over-expression of U6 snRNA
(Figure 4). This suggests that the growth defects in these
strains is in part due to reduced U6 snRNA levels and in
part due to alterations in deadenylation, which might
aﬀect some aspect of mRNA decay.
Lsm1 over-expression does not globally alter mRNA decay
The strong synthetic growth defects seen in the pop2D and
ccr4D strain with over-expression of Lsm1 on a GAL 2m
plasmid led us to hypothesize that Lsm1 over-expression
could also alter mRNA decay in some manner. This was
also supported by the fact that the strong synthetic growth
defects in ccr4D and pop2D over-expressing LSM1 was
only partially rescued by increasing U6 levels. To test if
Lsm1 over-expression aﬀects decapping, we examined the
eﬀects of LSM1 over-expression on mRNA decay in a
wild-type strain using the MFA2pG mRNA, which is a
commonly used reporter for mRNA decapping in yeast
(38). In order to analyze the decay of MFA2pG mRNA,
we expressed it as a low-copy, galactose-inducible pro-
moter fusion along with our GAL-LSM1 2m plasmid.
Cells were grown in galactose and transcription was
repressed by the addition of 4% dextrose (22), with sam-
ples taken for RNA analysis over a brief time course
to avoid impacting the pool of Lsm1 protein whose half-
life has been reported to be 76min (39). We observed no
signiﬁcant change in the decay rate of the MFA2pG
mRNA in a wild-type strain over-expressing Lsm1 as com-
pared to a vector control (t1/2 less than 50 for both).
Similarly, over-expressing Lsm1 at moderate levels on a
GAL-LSM1 CEN plasmid did not aﬀect the decay proﬁle
of the MFA2pG mRNA (data not shown). This indicates
that Lsm1 over-expression does not have a strong eﬀect
on the decay of all mRNAs although it remains possible
that Lsm1 over-expression aﬀects the decay of a subset
of mRNAs.
DISCUSSION
Lsm1 over-expression alters pre-mRNA splicing
In this work, we provide several lines of evidence that
Lsm1 over-expression can inhibit cell growth in budding
yeast by aﬀecting the biogenesis and/or function of the
U6 snRNA. First, over-expression of Lsm1 inhibited
growth and decreased the levels of the U6 snRNA
(Figures 1, 2 and 3). Second, the toxicity of the Lsm1
over-expression, and in certain strains its impact on spli-
cing, was increased in the lsm7D, lhp1D and snu66D
strains, all of which impact in some manner on the func-
tion/biogenesis of the U6 snRNP (Figures 1, 2 and 3).
Third, over-expression of the U6 snRNA rescued growth
and the splicing defect in some strains mutant for U6
snRNP function (Figures 4 and 5). The simplest inter-
pretation of these observations is that Lsm1 over-
expression impacts on U6 snRNA by depleting the levels
of the Lsm2-8 complex due to competition between
Lsm1 and Lsm8 for the Lsm2-7 complex members. This
interpretation is also consistent with synthetic growth
defects, as well as depletion of U6 snRNA levels, seen
when LSM1 was over-expressed in an lsm8-1 mutant
and with the observation that LSM1 over-expression
increases the concentration of Lsm7p in cytoplasmic
foci, presumably reﬂecting an increased formation of the
Lsm1-7p complex (18).
Our results suggest that Lsm1 over-expression can
impact on the U6 snRNP in two manners depending on
other alterations in the strains. In the lsm7D strain, the
primary eﬀect is on the levels of the U6 snRNA, and
over-expression of the U6 snRNA can suppress the
growth defect seen in these cases. This is consistent with
other observations that in an otherwise wild-type strain
the predominant role of the Lsm2-8 complex is to enhance
the stability of the U6 snRNA (29,40). However, in
the snu66D, over-expression of the U6 snRNA fails to
suppress the Lsm1 growth and splicing phenotypes result-
ing from Lsm1 over-expression (Figures 4 and 5). The
simplest interpretation here is that when Snu66, a com-
ponent of the U4/U6/U5 tri-snRNP, is missing, the
Lsm2-8 complex now plays a more important role in
the tri-snRNP’s function in splicing. Thus, even when
U6 snRNA is over-expressed any resulting U4/U6/U5
complex lacking both the Snu66 and Lsm2-8 proteins
would be defective for function.
A clear implication of these observations is that changes
in Lsm1 levels might impact on splicing in pancreatic
tumors. Our studies reveal that when Lsm1 is over-
expressed in yeast at moderate levels comparable to that
observed in cancer cells (7), splicing is altered due to a
depletion in U6 snRNA levels. In this light, it is nota-
ble that alterations in the splicing machinery have been
previously described in human pancreatic tumors and
transgenic mouse models. For instance, a serine/arginine
Figure 5. Synthetic splicing defects due to LSM1 over-expression can
be rescued by increasing levels of U6. Total RNA (20mg) from
BY4741(WT) and isogenic deletion strains transformed as indicated:
‘+’ in a row indicates expression of either GAL-LSM1 2m (pRP1840,
OE 2m LSM1) and/or pSNR6 (OE U6), ‘–’ indicates that the control
vector was used. Samples were electrophoresed on 8M Urea, 6% acry-
lamide gels and blotted by northern using a probe for U3 snoRNA.
U14 snoRNA is included as a normalization control. U6 snRNA probe
conﬁrms its over-expression. Marker sizes are noted.
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shown to be upregulated in pancreatic tumors and its
downregulation correlated to decreased proliferation and
increased apoptosis in these tumors (41). In addition, an
analysis of genomic changes in an Ela-c-myc transgenic
mouse model for pancreatic cancer revealed that splicing
factors and spliceosome-related genes were part of a major
class of genes upregulated in primary tumors and liver
metastatic regions as compared to normal pancreas (42).
Hence, it is possible that LSM1 over-expression also
contributes to changes in splicing patterns by altering
the stoichiometry of the spliceosomal machinery, allowing
for carcinogenesis to occur in pancreatic cells. An impli-
cation of this analysis, and the increased toxicity of Lsm1
over-expression in yeast strains compromised for U6
snRNA function, is that therapies directed at reducing
U6 snRNA biogenesis and/or function might be eﬀective
therapies for any tumor over-expressing Lsm1.
LSM1 over-expression decreases cell viability
when deadenylation is inhibited
We also provide evidence that Lsm1 over-expression leads
to a change in the cells’ requirement for diﬀerent mRNA
decay factors. Speciﬁcally, we observed that the toxicity of
the Lsm1 over-expression was increased in ccr4D and
pop2D strains (Figure 1C), which are compromised for
the predominant cytoplasmic deadenylase (35). Moreover,
the synthetic growth defects in these deadenylase mutants
could only be partially rescued by increasing U6 snRNA
levels (Figure 4). Overall, these results indicate that
some process of mRNA decay is altered by Lsm1 over-
expression, perhaps due to the assembly of mRNA decay
complexes that are defective in function. However, since
we did not observe an alteration in the MFA2pG mRNA,
any alterations in degradation must be limited to subsets
of mRNAs.
Prior studies in human cells do suggest that altera-
tions in the decay of subsets of mRNAs may exist in
Lsm1 over-expressing cancers. Array analyses of how
Lsm1 over-expression aﬀects the transcriptome (2,7)
have demonstrated that increased Lsm1 expression alters
levels of certain transcripts, some of which encode factors
important in carcinogenesis. However, only one example
is published providing an mRNA decay analysis. The
p21/Cip1 mRNA, encoding a cyclin-dependent kinase
inhibitor (43), was shown to be stabilized by targeted
reduction of Lsm1 in a cancer cell line, yet this did not
correspond to an increase in its protein expression (2).
Thus, it is still unclear whether therapeutic eﬀects achieved
with Lsm1 targeting in cancer cells are due to altering
the decay of speciﬁc transcripts. Nevertheless, the syn-
thetic lethality of Lsm1 over-expression in strains defec-
tive in mRNA deadenylation implies that therapeutic
agents targeting deadenylase activity could be possible
mechanisms for the treatment of tumors with over-
expression of Lsm1.
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